Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 4 |
2015 | 1 |
2016 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Anticancer Res. 2014 Apr;34(4):1657-62.
Anticancer Res. 2014.
PMID: 24692694
Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Matsuda Y, Yamauchi T, Hosono N, Uzui K, Negoro E, Morinaga K, Nishi R, Yoshida A, Kimura S, Maekawa T, Ueda T.
Matsuda Y, et al. Among authors: uzui k.
Cancer Sci. 2016 Jul;107(7):1029-38. doi: 10.1111/cas.12965. Epub 2016 Jun 21.
Cancer Sci. 2016.
PMID: 27166836
Free PMC article.
Item in Clipboard
Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
Yamauchi T, Uzui K, Nishi R, Shigemi H, Ueda T.
Yamauchi T, et al. Among authors: uzui k.
Anticancer Res. 2014 Oct;34(10):5487-94.
Anticancer Res. 2014.
PMID: 25275045
Item in Clipboard
Leukemia cells are sensitized to temozolomide, carmustine and melphalan by the inhibition of O6-methylguanine-DNA methyltransferase.
Arai H, Yamauchi T, Uzui K, Ueda T.
Arai H, et al. Among authors: uzui k.
Oncol Lett. 2015 Aug;10(2):845-849. doi: 10.3892/ol.2015.3307. Epub 2015 Jun 2.
Oncol Lett. 2015.
PMID: 26622581
Free PMC article.
Item in Clipboard
Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells.
Yamauchi T, Uzui K, Shigemi H, Negoro E, Yoshida A, Ueda T.
Yamauchi T, et al. Among authors: uzui k.
Cancer Sci. 2013 Jul;104(7):926-33. doi: 10.1111/cas.12164. Epub 2013 May 12.
Cancer Sci. 2013.
PMID: 23557198
Free PMC article.
Item in Clipboard
A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T, Uzui K, Nishi R, Tasaki T, Ueda T.
Yamauchi T, et al. Among authors: uzui k.
Anticancer Res. 2014 Sep;34(9):4885-92.
Anticancer Res. 2014.
PMID: 25202070
Item in Clipboard
Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T, Uzui K, Nishi R, Shigemi H, Ueda T.
Yamauchi T, et al. Among authors: uzui k.
BMC Cancer. 2014 Jul 29;14:547. doi: 10.1186/1471-2407-14-547.
BMC Cancer. 2014.
PMID: 25070259
Free PMC article.
Item in Clipboard
Cite
Cite